openPR Logo
Press release

Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) over potential Wrongdoing

04-21-2022 12:53 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

An investigation was announced for long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors and officers of Revance Therapeutics, Inc.

Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: RVNC stocks follows a lawsuit filed against Revance Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: RVNC stocks, concerns whether certain Revance Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that quality control deficiencies existed at the Company's manufacturing facility for DAXI, that the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form, that accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) over potential Wrongdoing here

News-ID: 2607608 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, Inc. (NYSE: DV)
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Revance

Aesthetic Service Market Is Booming Worldwide | Allergan, Galderma, Merz Pharmac …
The Global Aesthetic Service Market is estimated to be valued at USD 21.94 Bn in 2025 and is expected to reach USD 36.40 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032. The qualitative latest Research report (2025-2032) on the Aesthetic Service Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes
Lip Augmentation Market Trends and Forecast | Key Players: Revance Therapeutics, …
Lip Augmentation Market Overview The global lip augmentation market is projected to grow from USD 3.1 billion in 2024 to USD 6.1 billion by 2033, exhibiting a CAGR of 7.78% during the forecast period. Coherent Market Insights is pleased to release its latest Lip Augmentation Market research report, offering an in-depth analysis of the U.S. Lip Augmentation Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional
Medical Aesthetics Market Thrives Amid Rising Cosmetic Procedures Demand | Aller …
Medical Aesthetics Market Overview Medical Aesthetics Market is projected to grow from USD 14.23 billion in 2023 to USD 34.68 billion by 2032, registering a CAGR of 10.5% during the forecast period. The latest report (2025-2032) on the Medical Aesthetics Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition. It explores market size, revenue, production, consumption, and CAGR, using reliable research methods for accuracy.
Facial Injectable Market Is Booming So Rapidly | Evolus, Hugel, Revance
The Global Facial Injectable Market Size is estimated at $12.9 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.1% to reach $30.7 Billion by 2034. The latest study released on the Global Facial Injectable Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Facial Injectable market study covers significant research data and proofs to be a handy resource document for
Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVN …
An investor in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) filed a lawsuit over alleged Securities Laws violations by Revance Therapeutics, Inc. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and for certain investors are short and strict deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Newark, CA based Revance Therapeutics, Inc.,
Investigation announced for Investors in shares of Revance Therapeutics, Inc. (N …
An investigation was announced over potential securities laws violations by Revance Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Revance Therapeutics, Inc. regarding its business, its prospects and its operations were